4D Molecular Therapeutics, Inc. (FDMT)
10.80
-1.05
(-8.86%)
USD |
NASDAQ |
Oct 23, 16:00
10.78
-0.02
(-0.23%)
After-Hours: 20:00
4D Molecular Therapeutics Total Liabilities (Quarterly) : 84.96M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 84.96M |
| March 31, 2026 | 61.07M |
| December 31, 2025 | 61.05M |
| September 30, 2025 | 55.00M |
| June 30, 2025 | 52.75M |
| March 31, 2025 | 46.01M |
| December 31, 2024 | 49.78M |
| September 30, 2024 | 51.08M |
| June 30, 2024 | 31.78M |
| March 31, 2024 | 29.32M |
| December 31, 2023 | |
| September 30, 2023 | 31.68M |
| June 30, 2023 | 27.36M |
| March 31, 2023 | 25.42M |
| Date | Value |
|---|---|
| December 31, 2022 | 30.51M |
| September 30, 2022 | 28.72M |
| June 30, 2022 | 30.42M |
| March 31, 2022 | 28.87M |
| December 31, 2021 | 34.38M |
| September 30, 2021 | 16.48M |
| June 30, 2021 | 14.29M |
| March 31, 2021 | 27.68M |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 28.22M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| Anika Therapeutics, Inc. | 46.19M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
| Imunon, Inc. | 10.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 492.62M |
| Shareholders Equity (Quarterly) | 407.66M |
| Debt to Equity Ratio | 0.0962 |
| Current Ratio | 8.033 |
| Net Debt Paydown Yield | -0.42% |